The FDA was justified in rejecting Merck's accelerated approval bid for its lung cancer drug

FDA approvals, clinical trial design, psychedelic drug policy, compounding pharmacy regulation, and drug scheduling.

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.

Cancer treatment, oncology drug access, hematologic malignancies, and cancer drug policy.

Cancer screening, immunotherapy, CAR-T therapies, targeted drugs, biomarkers, and AI in oncology.